Journal of International Oncology ›› 2023, Vol. 50 ›› Issue (5): 268-273.doi: 10.3760/cma.j.cn371439-20230307-00054
• Original Articles • Previous Articles Next Articles
Chen Zhuo1, Tao Jun2(), Chen Lin2, Ke Jing2
Received:
2023-03-07
Revised:
2023-04-12
Online:
2023-05-08
Published:
2023-06-27
Contact:
Tao Jun
E-mail:watxy0828@163.com
Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer[J]. Journal of International Oncology, 2023, 50(5): 268-273.
"
临床病理特征 | 例数 | 外周血miR-194 | t值 | P值 | 粪便miR-143 | t值 | P值 |
---|---|---|---|---|---|---|---|
年龄(岁) | |||||||
≥65 | 38 | 1.75±0.42 | 0.83 | 0.408 | 1.86±0.32 | 1.17 | 0.244 |
<65 | 45 | 1.83±0.45 | 1.95±0.37 | ||||
TNM分期 | |||||||
Ⅰ~Ⅱ期 | 27 | 2.01±0.52 | 1.03 | 0.307 | 1.96±0.38 | 0.11 | 0.909 |
Ⅲ~Ⅳ期 | 56 | 1.89±0.46 | 2.11±0.42 | ||||
淋巴结转移 | |||||||
有 | 32 | 1.87±0.47 | 0.37 | 0.711 | 1.92±0.43 | 1.85 | 0.068 |
无 | 51 | 1.91±0.48 | 1.78±0.26 | ||||
远处转移 | |||||||
有 | 24 | 1.86±0.49 | 0.41 | 0.683 | 2.12±0.47 | 1.72 | 0.089 |
无 | 59 | 1.91±0.51 | 1.93±0.45 |
[1] | 潘辉, 黄琰璎, 王国新, 等. 粪便基因SDC2和BMP3甲基化联合检测在结直肠癌筛查中的价值[J]. 中国医药导报, 2020, 17(11): 15-19. |
[2] |
Zhou R, Qiu P, Wang H, et al. Identification of microRNA-16-5p and microRNA-21-5p in feces as potential noninvasive biomarkers for inflammatory bowel disease[J]. Aging (Albany NY), 2021, 13(3): 4634-4646. DOI: 10.18632/aging.202428.
doi: 10.18632/aging.202428 |
[3] |
Moody L, Dvoretskiy S, An R, et al. The efficacy of miR-20a as a diagnostic and prognostic biomarker for colorectal cancer: a systematic review and meta-analysis[J]. Cancers (Basel), 2019, 11(8): 1111. DOI: 10.3390/cancers11081111.
doi: 10.3390/cancers11081111 |
[4] |
邵书先, 沈忠, 张秀峰, 等. 粪便多基因联合检测在结直肠癌早期筛查中的应用[J]. 中华全科医学, 2020, 18(11): 1819-1822. DOI: 10.16766/j.cnki.issn.1674-4152.001627.
doi: 10.16766/j.cnki.issn.1674-4152.001627 |
[5] |
Yau TO, Tang CM, Harriss EK, et al. Faecal microRNAs as a non-invasive tool in the diagnosis of colonic adenomas and colorectal cancer: a meta-analysis[J]. Sci Rep, 2019, 9(1): 9491. DOI: 10.1038/s41598-019-45570-9.
doi: 10.1038/s41598-019-45570-9 pmid: 31263200 |
[6] |
Duran-Sanchon S, Moreno L, Augé JM, et al. Identification and validation of microRNA profiles in fecal samples for detection of colorectal cancer[J]. Gastroenterology, 2020, 158(4): 947-957.e4. DOI: 10.1053/j.gastro.2019.10.005.
doi: S0016-5085(19)41439-X pmid: 31622624 |
[7] |
朱富强, 唐亚萍, 彭树松, 等. 粪便中miR-31的表达对结直肠癌早期筛查的价值[J]. 中国医师杂志, 2019, 21(8): 1232-1233. DOI: 10.3760/cma.j.issn.1008-1372.2019.08.032.
doi: 10.3760/cma.j.issn.1008-1372.2019.08.032 |
[8] |
Duran-Sanchon S, Moreno L, Gómez-Matas J, et al. Fecal microRNA-based algorithm increases effectiveness of fecal immunochemical test-based screening for colorectal cancer[J]. Clin Gastroenterol Hepatol, 2021, 19(2): 323-330.e1. DOI: 10.1016/j.cgh.2020.02.043.
doi: 10.1016/j.cgh.2020.02.043 |
[9] |
Brînzan C, Aşchie M, Cozaru G, et al. The diagnostic value of miR-92a, -143, and -145 expression levels in patients with colorectal adenocarcinoma from Romania[J]. Medicine (Baltimore), 2020, 99(35): e21895. DOI: 10.1097/MD.0000000000021895.
doi: 10.1097/MD.0000000000021895 |
[10] |
冷晓旭, 房静远. 粪便标志物DNA和RNA筛查结直肠癌特性分析[J]. 中华医学杂志, 2020, 100(42): 3373-3376. DOI: 10.3760/cma.j.cn112137-20200228-00507.
doi: 10.3760/cma.j.cn112137-20200228-00507 |
[11] |
Ardila HJ, Sanabria-Salas MC, Meneses X, et al. Circulating miR-141-3p, miR-143-3p and miR-200c-3p are differentially expressed in colorectal cancer and advanced adenomas[J]. Mol Clin Oncol, 2019, 11(2): 201-207. DOI: 10.3892/mco.2019.1876.
doi: 10.3892/mco.2019.1876 pmid: 31316774 |
[12] |
Sahami-Fard MH, Kheirandish S, Sheikhha MH. Expression levels of miR-143-3p and -424-5p in colorectal cancer and their clinical significance[J]. Cancer Biomark, 2019, 24(3): 291-297. DOI: 10.3233/CBM-182171.
doi: 10.3233/CBM-182171 pmid: 30883340 |
[13] |
张江国, 汪之沫. 粪便多靶点DNA和miR-135b表达联合检测诊断结直肠癌的价值[J]. 山东医药, 2019, 59(19): 60-63. DOI: 10.3969/j.issn.1002-266X.2019.19.016.
doi: 10.3969/j.issn.1002-266X.2019.19.016 |
[14] |
Yang Q, Zheng W, Shen Z, et al. MicroRNA binding site polymorphisms of the long-chain noncoding RNA MALAT1 are associated with risk and prognosis of colorectal cancer in Chinese Han population[J]. Genet Test Mol Biomarkers, 2020, 24(5): 239-248. DOI: 10.1089/gtmb.2020.0013.
doi: 10.1089/gtmb.2020.0013 |
[15] |
张肖丽, 张月晓, 李萍, 等. 结肠癌患者血清miRNA表达意义及与肠道菌群失调关联性[J]. 中国微生态学杂志, 2022, 34(1): 46-51. DOI: 10.13381/j.cnki.cjm.202201008.
doi: 10.13381/j.cnki.cjm.202201008 |
[16] |
Feng Y, Xu Y, Gao Y, et al. A novel lncRNA SOX2OT promotes the malignancy of human colorectal cancer by interacting with miR-194-5p/SOX5 axis[J]. Cell Death Dis, 2021, 12(5): 499. DOI: 10.1038/s41419-021-03756-y.
doi: 10.1038/s41419-021-03756-y pmid: 33993197 |
[17] |
Wu S, Sun H, Wang Y, et al. MALAT1 rs664589 polymorphism inhibits binding to miR-194-5p, contributing to colorectal cancer risk, growth, and metastasis[J]. Cancer Res, 2019, 79(20): 5432-5441. DOI: 10.1158/0008-5472.CAN-19-0773.
doi: 10.1158/0008-5472.CAN-19-0773 pmid: 31311811 |
[18] |
Li G, Wang Q, Li Z, et al. Serum miR-21 and miR-210 as promising non-invasive biomarkers for the diagnosis and prognosis of colorectal cancer[J]. Rev Esp Enferm Dig, 2020, 112(11): 832-837. DOI: 10.17235/reed.2020.6801/2019.
doi: 10.17235/reed.2020.6801/2019 pmid: 33054296 |
[19] |
连戴政, 刘雅洁. 粪便miRNA标志物在结直肠癌筛选和诊断中的应用研究进展[J]. 肿瘤学杂志, 2019, 25(4): 310-314. DOI: 10.11735/j.issn.1671-170X.2019.04.B005.
doi: 10.11735/j.issn.1671-170X.2019.04.B005 |
[20] |
Peng Q, Shen Y, Zhao P, et al. Biomarker roles identification of miR-106 family for predicting the risk and poor survival of colorectal cancer[J]. BMC Cancer, 2020, 20(1): 506. DOI: 10.1186/s12885-020-06863-9.
doi: 10.1186/s12885-020-06863-9 pmid: 32493303 |
[21] |
Choi HH, Cho YS, Choi JH, et al. Stool-based miR-92a and miR-144* as noninvasive biomarkers for colorectal cancer screening[J]. Oncology, 2019, 97(3): 173-179. DOI: 10.1159/000500639.
doi: 10.1159/000500639 pmid: 31216561 |
[22] |
王胜, 吴英光, 何孟胜. 血清miR-200a、miR-190联合检测在结直肠癌诊断及预后评估中的应用价值[J]. 国际消化病杂志, 2019, 39(4): 286-290. DOI: 10.3969/j.issn.1673-534X.2019.04.011.
doi: 10.3969/j.issn.1673-534X.2019.04.011 |
[23] |
Xu M, Chen X, Lin K, et al. lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer[J]. J Hematol Oncol, 2019, 12(1): 3. DOI: 10.1186/s13045-018-0690-5.
doi: 10.1186/s13045-018-0690-5 |
[24] |
Xu K, Zhan Y, Yuan Z, et al. Hypoxia induces drug resistance in colorectal cancer through the HIF-1α/miR-338-5p/IL-6 feedback loop[J]. Mol Ther, 2019, 27(10): 1810-1824. DOI: 10.1016/j.ymthe.2019.05.017.
doi: S1525-0016(19)30264-3 pmid: 31208913 |
[1] | Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375. |
[2] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[3] | Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285. |
[4] | Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118. |
[5] | Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474. |
[6] | Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163. |
[7] | Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190. |
[8] | Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722. |
[9] | Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687. |
[10] | Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46. |
[11] | Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang. Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 555-559. |
[12] | He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang. Predictive value of inflammatory markers in colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 560-563. |
[13] | Zhao Ying, Zhang Gehong. Study on the correlations between AGR, PLR and NLR changes and chemotherapy efficacy of metastatic colorectal cancer [J]. Journal of International Oncology, 2022, 49(8): 473-477. |
[14] | Huang Mengpan, Wang Xuehong, Lu Yongfu. Mechanism of FOXA2 in colorectal cancer and its application in diagnosis and treatment [J]. Journal of International Oncology, 2022, 49(8): 490-493. |
[15] | Liu Song, Yu Guangji, Wang Qingdong. Efficacy and influencing factors of DEBIRI-TACE combined with regorafenib in the third-line or above treatment of colorectal cancer liver metastases [J]. Journal of International Oncology, 2022, 49(7): 400-407. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||